Journals / Annals of Medical Research / 2022 / Cilt: 29 - Sayı: 3

Investigation of protective effects of misoprostol against paclitaxel-induced ovarian damage in rats

Pages
233–239
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: As a result, it shows that the use of MP can improve PTX-induced ovarian damage by preventing oxidative damage.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: The main objective of our study was to examine the protection of misoprostol (MP) on paclitaxel (PTX) side effects in rat ovaries.
📊
Key Findings & Data:Materials and Methods: Twenty-one female Sprague-Dawley rats were provided to form 3 groups, each containing seven rats: In group 1 (control group), was given 1 mL of 0.9% NaCl intraperitoneally (i.p.) and 1 mL of 0.9% NaCl orally for 6 days.
💡
Conclusion & Impact:Conclusion: As a result, it shows that the use of MP can improve PTX-induced ovarian damage by preventing oxidative damage.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: The main objective of our study was to examine the protection of misoprostol (MP) on paclitaxel (PTX) side effects in rat ovaries. Materials and Methods: Twenty-one female Sprague-Dawley rats were provided to form 3 groups, each containing seven rats: In group 1 (control group), was given 1 mL of 0.9% NaCl intraperitoneally (i.p.) and 1 mL of 0.9% NaCl orally for 6 days. In treatment groups, each rat was injected 2 mg/kg PTX i.p. on days 0, 2, 4, and 6 of the study and 0.2 mg/kg/day MP was given by oral gavage for 6 days. Results: Levels of malondialdehyde (MDA), and glutathione (GSH), activities of superoxide dismutase (SOD), and catalase (CAT) of tissue samples were measured. Histopathological alterations in PTX administrated rats were seen such as, degenerative changes in granulosa cells, decrease in number of growing and tertiary follicles and increasing active caspase 3 (Casp-3) positive immunoreaction in theca, granulosa and stromal cells. Conclusion: As a result, it shows that the use of MP can improve PTX-induced ovarian damage by preventing oxidative damage.

🔖

Cite This Article

BİLGİÇ, S., AKTAŞ, I. (2022). Investigation of protective effects of misoprostol against paclitaxel-induced ovarian damage in rats. Annals of Medical Research, Cilt: 29 - Sayı: 3, 233–239. https://ajindex.com/articles/446144

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Massey AE, Sikander M, Chauhan N, et al. Next-generation paclitaxel-nanoparticle formulation for pancreatic cancer treatment. Nanomed-Nanotechnol. 2019;20:1-15
  2. Singla AK, Garg A, Aggarwal D. Paclitaxel and its formulations. Int J Pharm. 2002;235:179-192
  3. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer. 2004;4(4):253-65
  4. Torino F, Barnabei A, De Vecchis L, Appetecchia M, Strigan L, Corsello SM. Recognizing menopause in women with amenorrhea induced by cytotoxic chemotherapy for endocrineresponsive early breast cancer. Endocr Relat Cancer. 2012;19:21- 33
  5. Han HS, Ro J, Lee KS. et al. Analysis of chemotherapy-induced amenorrhea rates by three different anthracycline and taxane containing regimens for early breast cancer. Breast Cancer Res Treat. 2009;115:335-342
  6. Caffrey PB, Frenkel GD. Selenium compounds prevent the induction of drug resistance by cisplatin in human ovarian tumor xenografts in vivo. Cancer Chemother Pharmacol. 2000;46:74- 78
  7. Meirow D, Dor J, Kaufman B. et al. Cortical fibrosis and blood-vessels damage in human ovaries exposed to chemotherapy. Potential mechanisms of ovarian injury. Hum Reprod. 2007;22:1626-1633
  8. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116:791-798
  9. Bildik G, Akin N, Senbabaoglu F. et al. GnRH agonist leuprolide acetate does not confer any protection against ovarian damage induced by chemotherapy and radiation in vitro. Hum Reprod. 2015;30:2912-2925
  10. Mailhes JB, Carabatsos MJ, Young D, London SN, Bell M, Albertini DF. Taxol-induced meiotic maturation delay, spindle defects, and aneuploidy in mouse oocytes and zygotes. Mutat Res. 1999;423:79-90
  11. Ozcelik B, Turkyilmaz C, Ozgun MT, Serin IS, Batukan C, Ozdamar S, Ozturk A. Prevention of paclitaxel and cisplatin induced ovarian damage in rats by a gonadotropin-releasing hormone agonist. Fertil Steril. 2010;93:1609-1614
  12. Lopes F, Smith R, Anderson RA, Spears N. Docetaxel induces moderate ovarian toxicity in mice, primarily affecting granulosa cells of early growing follicles. Mol Hum Reprod. 2014;20:948-59
  13. Altmann KH, Gertsch J. Anticancer drugs from natüre-natural products as a unique source of new microtubule-stabilizing agents. Nat Prod Rep. 2007;24:327-357
  14. Elati A, Weeks AD. The use of misoprostol in obstetrics and gynaecology. BJ